Browsing articles in "Alzheimer's/Other Dementias"


Gut Microbiome Composition May be an Indicator of Preclinical Alzheimer’s Disease
June 23, 2023   

With Alzheimer’s disease (AD) becoming a global crisis, as lifespans increase and disease-modifying treatments remain aloof, there is mounting interest in identifying modifiable risk factors that may affect AD progression. The gut microbiome, and dysbiosis thereof, is being increasingly recognized as affecting many aspects of mental and neurological health. ..
 Continue reading (Members only)
Sleep-Disordered Breathing Tied to Brain Volumes in Amyloid-Positive Older Adults
June 19, 2023   

Sleep-disordered breathing (SDB) has been associated with increased amyloid deposition and dementia risk; however, the details of that relationship are yet to be fully evident. A recent study investigated SDB and volume of medial temporal lobe subregions (associated with episodic memory and often affected in AD) and the impact of amyloid beta pathology in ..
 Continue reading (Members only)
FDA Approves First Treatment for Agitation Associated with Alzheimer’s Dementia
May 10, 2023   

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application of brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia (AAD). This is the first FDA-approved treatment indicated for AAD in the United States...
 Continue reading
Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively
March 1, 2023   

The pathology of Alzheimer’s disease (AD) begins with a prolonged phase of beta-amyloid accumulation without symptoms. The duration of this phase varies widely depending on the individual. A recent prospective population-based study examined data from 2 prospective longitudinal cohorts...
 Continue reading (Members only)
The Future of Psychopharmacology
February 9, 2023   

It is an incredible time in terms of the development of new psychopharmacological agents with novel mechanisms of action. In this article, leading experts in the field of psychopharmacology discuss the most promising medications in Phase II and III clinical trials that are being investigated for schizophrenia, bipolar disorder, major depressive disorder, anxiety, substance use disorders, and dementia...
 Continue reading (Members only)
FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
January 23, 2023   

The U.S. Food and Drug Administration recently approved lecanemab, via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. This is the second of a novel category of medications approved for...
 Continue reading
'Convincing Evidence' Hearing Aids Reduce Dementia Risk
December 20, 2022   

With no truly effective treatment for dementia yet available, there is increased interest in lifestyle factors that may delay or prevent the onset of dementia. Previous studies have shown that hearing loss is associated with increased risk of dementia and cognitive decline. There are 3 main hypotheses for this association...
 Continue reading
Highlights from 2022 NEI Congress: Management of Agitation Associated With Alzheimer’s Dementia
November 6, 2022   

When a patient presents with agitation it represents a substantial challenge to mental health professionals, especially if the agitation is accompanied by psychotic symptoms or progresses to violence or aggression. At the 2022 NEI Congress, Dr. Stephen M. Stahl delivered a presentation on best practices for the management of agitation in patients with Alzheimer’s dementia...
 Continue reading
Alzheimer's Awareness Month
November 1, 2022   

October is ADHD Awareness Month. The goal of ADHD Awareness Month is to increase awareness and provide education about ADHD. ADHD continues through adolescence and into adulthood, affecting approximately 5% of the child population worldwide and 2% to 4% of the adult population worldwide...
 Continue reading
FDA Panel Rejects Pimavanserin for Alzheimer's Psychosis
June 21, 2022   

A U.S. Food and Drug Administration advisory panel voted 9:3 against the supplementary new drug application pimavanserin for the treatment of hallucinations and delusions related to Alzheimer's disease psychosis...
 Continue reading (Members only)
Top of Page